诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

未开盘 07-06 16:08:32

13.990

+0.910

+6.96%

最高14.550	最低13.090	成交量2,156万
今开13.100	昨收13.080	日振幅11.16%
总市值246.92亿	流通市值209.01亿	总股本17.65亿
成交额3.04亿	换手率1.44%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.99,"timestamp":1783325312010,"preClose":13.08,"halted":0,"volume":21561550,"delay":0,"changeRate":0.06957186544342508,"floatShares":1494000000,"shares":1764999999,"eps":0.38,"marketStatus":"未开盘","change":0.91,"latestTime":"07-06 16:08:32","open":13.1,"high":14.55,"low":13.09,"amount":303944614,"amplitude":0.111621,"askPrice":13.99,"askSize":10000,"bidPrice":13.98,"bidSize":44000,"shortable":3,"etf":0,"ttmEps":0.469,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783387800000},"marketStatusCode":0,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":13.08,"openAndCloseTimeList":[[1783301400000,1783310400000],[1783314000000,1783324800000]],"volumeRatio":1.4349592191488538,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":29.9,"timestamp":1783321200000,"preClose":30.18,"halted":0,"volume":18822800,"delay":0,"premium":"-59.45"}},"requestUrl":"/m/hq/s/09969/wiki","defaultTab":"wiki","newsList":[{"id":"1175912470","title":"诺诚健华2026年6月股份变动月报：A股新增发行2,418,300股","url":"https://stock-news.laohu8.com/highlight/detail?id=1175912470","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175912470?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:52","pubTimestamp":1783335141,"startTime":"0","endTime":"0","summary":"诺诚健华于2026年7月6日发布最新月报，披露2026年6月截至当月末的股本及股份变动情况。公司注册股本维持为25,000,000,000股，面值每股0.000002美元，注册股本总额仍为50,000美元，较上月未发生变动。公告显示，截至2026年6月30日，公司在香港联交所上市的普通股数量为1,493,798,235股，另有库存股份2,486,000股，合计1,496,284,235股，与上月底保持一致。据公告披露，6月主要变动源于2024年人民币股股份激励计划项下的首次授予，新增2,418,300股限制性股票。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649642211","title":"港股收盘(07.06) | 恒指收涨1.14% 医药、科网股全天走高 AI硬件股普遍重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2649642211","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649642211?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:38","pubTimestamp":1783327081,"startTime":"0","endTime":"0","summary":"截至收盘，涨4.82%，报452港元，成交额185.2亿港元，贡献恒指89.98点。另一边，机构爆料英伟达Kyber机架或遇延迟，PCB、光通信等AI硬件股下挫。截至收盘，德康农牧涨5.98%，报50.3港元；中粮家佳康涨4.9%，报1.07港元；牧原股份涨3.8%，报32.82港元。截至收盘，涨18.9%，报13.46港元。TCL电子全天走高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSImain","KWEB","ARTY","TCHmain","CHAT","JADE","02833","QTOC","AAXJ","CXSE","HHImain","01112","02800","FPA","FFEM","AGIX","XSOE","SOCL","TCHI","LDEM","AIPO","MHImain","09969","03115","82800","ODDS","513600","09939","159938","JEMA","HTCD.SI","03037","07200","EMC","FDNI","KCAI","MCHmain","07500","09115","BIDD","83115","VXUS","01888","VTHR","02419","MCHS","BKF","00700","HSI","ESPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198706155","title":"异动解读｜诺诚健华盘中上涨6.65%，自研ADC创新药ICP-B208完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1198706155","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198706155?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:59","pubTimestamp":1783303158,"startTime":"0","endTime":"0","summary":"7月6日，诺诚健华盘中上涨6.65%，报14.1港元，成交额7214.94万港元。消息面上，公司自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药，标志着该药物正式进入临床阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649461757","title":"诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649461757","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649461757?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:52","pubTimestamp":1783302720,"startTime":"0","endTime":"0","summary":"　　诺诚健华盘中涨超9%，截至发稿，股价上涨6.42%，现报13.92港元，成交额5426.90万港元。　　7月6日，据诺诚健华官微消息，公司宣布自主研发的靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药。基于诺诚健华自主研发的ADC技术平台，ICP-208由人源化抗CDH17抗体通过蛋白酶可裂解连接子与公司自主开发的强效有效载荷偶联而成，可精准靶向肿瘤细胞，同时最大限度减少脱靶效应。目前，全球尚无CDH17靶向ADC新药上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-06/doc-inifvqsf1795989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","NETL","09969","688428","MEDX","BK4080","159992","BK1161","BK0239","IBBQ","ADC","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649178286","title":"港股异动 | 诺诚健华(09969.HK)涨超8% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649178286","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649178286?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:43","pubTimestamp":1783302182,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","09969","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648549090","title":"诺诚健华（688428）披露根据2023年股权激励计划授出受限制股份单位，7月1日股价上涨3.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648549090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648549090?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:23","pubTimestamp":1782915793,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，诺诚健华报收于29.57元，较前一交易日上涨3.86%，最新总市值为522.52亿元。该股当日开盘28.38元，最高30.05元，最低27.06元，成交额达5.37亿元，换手率为6.89%。近日，诺诚健华医药有限公司披露公告显示，公司于2026年6月30日根据2023年股权激励计划向八名承授人授出1,910,000份受限制股份单位，占公司已发行股份总数约0.11%。1,480,000份受限制股份单位将在一至四年内分四期等额归属，其余430,000份以达成公司及个人层面业绩目标为归属条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648786597","title":"半导体设备板块短线走低，恒运昌跌超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648786597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648786597?lang=zh_cn&edition=full","pubTime":"2026-07-01 14:17","pubTimestamp":1782886664,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["688409","688037","688428","BK0251","688082","BK0259","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647515558","title":"诺诚健华(09969.HK)授出191万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2647515558","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647515558?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:26","pubTimestamp":1782818762,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647832239","title":"6月29日诺诚健华涨13.08%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647832239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647832239?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:39","pubTimestamp":1782722398,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日诺诚健华涨13.08%，收盘报28.61元，换手率8.5%，成交量23.01万手，成交额6.36亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值2.9889，较上一交易日下跌3.51%，近一年下跌3.06%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647223153","title":"诺诚健华涨13.08%，长城国瑞证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647223153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647223153?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:39","pubTimestamp":1782722392,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨13.08%，收盘报28.61元。2026年3月31日，长城国瑞证券研究员胡晨曦,魏钰琪发布了对诺诚健华的研报《盈利拐点初现，商业化放量与技术授权双轮驱动》，该研报对诺诚健华给出“买入”评级。因此，我们维持其“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。诺诚健华个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159164688","title":"港股生物医药板块反弹，荣昌生物涨超16%，创新药主线全面爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=1159164688","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159164688?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:55","pubTimestamp":1782701710,"startTime":"0","endTime":"0","summary":"6月29日，港股生物医药股集体走强，荣昌生物涨超16%，康诺亚-B、诺诚健华、康方生物均涨超12%。板块上涨主要受创新药出海、BD交易活跃及临床管线进展预期带动，资金加速回流创新药和CXO方向。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","02269","09995","03347","02162","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU0326950275.SGD","LU1226287792.SGD","LU0072913022.USD","01093","LU0348735423.USD","159992","LU1993786604.SGD","IE00B5MMRT66.SGD","LU0348825331.USD","HK0000165453.HKD","LU1008478684.HKD","02157","LU0417516902.SGD","BK1583","BK1574","06855","01530","LU0348784397.USD","LU0417516571.SGD","LU2476274720.SGD","LU0315179316.USD","LU2476274308.USD","LU0348783233.USD","LU0348827113.USD","09926","02228","IE00B543WZ88.USD","LU1969619763.USD","LU0348766576.USD","LU0348767384.USD","LU0067412154.USD","LU0140636845.USD","LU1328277881.USD","LU1961090484.USD","09969","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1720050803.USD","02162","09995","LU1226287529.USD","LU1960683339.HKD","LU0540923850.HKD","IE00BZ08YR35.GBP","06978","02637","LU1951186391.HKD","BK1141","LU1226288253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840353","title":"诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840353","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840353?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:16","pubTimestamp":1782465406,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向2名董事发行79.5万股新人民币股份(于2024年12月17日采纳)。于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向2名高级管理人员发行20万股新人民币股份(于2024年12月17日采纳)。于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向70名激励对象发行142.23万股新人民币股份(于2024年12月17日采纳)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MCNHmain","BK1161","MUCmain","UCmain","BK0239","BK1574","CNHmain","09969","CYB","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197130689","title":"诺诚健华增发241.83万股人民币股份，总股本增至17.65亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1197130689","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197130689?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:16","pubTimestamp":1782465401,"startTime":"0","endTime":"0","summary":"诺诚健华于2026年6月26日发布翌日披露报表，公告显示，公司根据2024年人民币股股份激励计划首次授予部分第一归属期的归属结果，合计向2名董事、2名高级管理人员及70名激励对象发行人民币股份2,418,300股，约占本次变动前公司已发行股份总数的0.14%，每股发行价为人民币6.65元，募资总额约1,608.17万元人民币。其中，香港交易所上市股份数量维持1,493,798,235股和2,486,000股库藏股不变；上海证券交易所科创板上市的人民币股份则由268,359,717股增至270,778,017股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺诚健华增发241.83万股人民币股份，总股本增至17.65亿股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645902892","title":"诺诚健华：多位股东计划减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645902892","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645902892?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:54","pubTimestamp":1782298440,"startTime":"0","endTime":"0","summary":"诺诚健华：多位股东计划减持公司股份","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781555560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","688428","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645383250","title":"诺诚健华（688428）披露2024年科创板限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市，6月23日股价上涨2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645383250","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645383250?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:14","pubTimestamp":1782224091,"startTime":"0","endTime":"0","summary":"近日，诺诚健华医药有限公司发布《关于2024年科创板限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告》。公告显示，公司完成2024年科创板限制性股票激励计划首次授予部分第一个归属期的股份登记，本次归属股票数量为2,418,300股，来源为公司向激励对象定向发行人民币普通股，归属人数为74人，其中包含董事、高级管理人员及核心技术人等。本次归属新增股份已于2026年6月22日完成登记，上市流通日期为2026年6月26日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","09969","159982","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001206","title":"医药板块逆市走高 山东新华制药(00719)涨23.59%、康诺亚-B(02162)涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001206","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645001206?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:08","pubTimestamp":1782180500,"startTime":"0","endTime":"0","summary":"市场交易结构出现变化，医药与科技板块不再呈现明显跷跷板效应，医疗服务、CXO赛道带动板块韧性修复。临近二季度末，市场开始提前交易行业业绩预期，资金重点布局两大主线，分别为商业化放量提速的创新药标的，以及受益于投融资回暖的CXO、生命科学上游龙头。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984274","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","09995","09688","BK1576","LU0052750758.USD","IE00B0JY6N72.USD","LU0417516902.SGD","LU0516422952.EUR","LU0348783233.USD","06990","LU1720050803.USD","LU0516423091.SGD","LU0039217434.USD","LU0456827905.SGD","LU0516422366.SGD","LU0588546209.SGD","LU0326950275.SGD","LU1251922891.USD","LU0359202008.SGD","LU1242518857.USD","LU1303224171.USD","LU0051755006.USD","LU1880383366.USD","LU0140636845.USD","BK1589","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","00719","BK1161","LU0359201612.USD","LU0456846285.SGD","01877","LU2328871848.SGD","BK1191","09926","LU3063872942.SGD","LU0307460666.USD","159938","LU0320764599.SGD","LU0327786744.USD","02268","SG9999002562.SGD","02162","LU0856984785.SGD","LU2039709279.SGD","02269","06160","BK1583","09969","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644706351","title":"6月18日诺诚健华涨6.90%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644706351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644706351?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:36","pubTimestamp":1781771817,"startTime":"0","endTime":"0","summary":"证券之星消息，6月18日诺诚健华涨6.90%，收盘报23.86元，换手率5.17%，成交量13.88万手，成交额3.26亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值2.785，较上一交易日下跌1.15%，近一年下跌11.13%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800028753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","BK1161","BK0239","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644762357","title":"港股异动 | 诺诚健华(09969)盘中涨超5% 坦昔妥单抗联合疗法治疗初治DLBCLⅢ期研究于EHA年会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2644762357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644762357?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:55","pubTimestamp":1781751327,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华盘中涨超5%，截至发稿，涨3.29%，报10.69港元，成交额4304.89万港元。消息面上，6月18日，据诺诚健华官微消息，公司宣布，在2026欧洲血液学协会年会最高级别的全体大会上，坦昔妥单抗联合疗法全球III期frontMIND研究结果以口头报告形式重磅发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK1161","BK4585","BK1574","09969","BK0239","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643676393","title":"诺诚健华（688428）披露2023年激励计划首次授予部分第三个归属期符合归属条件公告，6月16日股价下跌2.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643676393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643676393?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:20","pubTimestamp":1781619621,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，诺诚健华报收于22.56元，较前一交易日下跌2.42%，最新总市值为398.1亿元。近日，诺诚健华医药有限公司发布《关于2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期符合归属条件的公告》。公告显示，本次拟归属限制性股票数量为2,044,750股，其中首次授予部分1,641,500股，预留授予部分403,250股，股票来源为公司向激励对象定向发行人民币普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","688428","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.1514},{"period":"1month","weight":0.3261},{"period":"3month","weight":-0.0986},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.0197},{"period":"ytd","weight":0.1374}],"compareEarnings":[{"period":"1week","weight":0.0256},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0597},{"period":"6month","weight":-0.1074},{"period":"1year","weight":-0.0125},{"period":"ytd","weight":-0.0786}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.102464},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.059233},{"month":6,"riseRate":0.857143,"avgChangeRate":0.113731},{"month":7,"riseRate":0.571429,"avgChangeRate":0.059306},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}